BioNano Genomics Inc vs Impinj Inc — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Impinj Inc trades at $147.48 (market cap $4.40B). The key difference: Impinj Inc is far larger — about 333.3× BioNano Genomics Inc's market cap, and Impinj Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PI | |
|---|---|---|
Market Cap | $13.20M | $4.40B |
Sector | Health | Technology |
52-Week High | $4.92 | $241.91 |
52-Week Low | $1.09 | $91.34 |
Enterprise Value | $15.81M | $4.54B |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Impinj (PI) trades at $146.02, up 1.38% with a bullish technical signal supported by moving averages. The company shows mixed fundamentals with a negative net income margin of -7.66% but beat Q1 2026 EPS estimates. Revenue remains stable at $361M annually, though profitability challenges persist with elevated valuation ratios like P/S of 11.89. Analyst consensus is strongly bullish with 73% buy ratings and a $167.50 price target.
Outlook remains cautiously optimistic given strong analyst support and technical momentum, but investors face risks from insider selling and ongoing profitability challenges. The stock offers potential upside to consensus targets if execution improves, though negative margins and competitive pressures warrant careful monitoring.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →